Immunologist Dr. Kathrin de la Rosa joined the MDC in July 2018 and leads the research group on Immune Mechanisms and Human Antibodies. Even as a doctoral student, her work revolved around the B cell – the cell type that produces antibodies and is therefore indispensable for immune defense in the human body. “While at the University Medical Center Freiburg, I studied patients with weakened immune systems due to B-cell defects,” says the biologist.
She found this field of research so fascinating that she went on to study B cells in even more depth, conducting her postdoctoral studies with the immunologist Antonio Lanzavecchia in Switzerland. “There, I learned how to isolate human antibodies in order to analyze the immune response to infectious diseases and thus lay the groundwork for developing new therapeutics and vaccines.”
In our #QuestionOfTheDay series, she talks about her research and the daily work under challenging conditions:
The MDC was in minimal operation mode from March 18 to May 4 in order to slow down the spread of the SARS coronavirus-2 and protect its employees. The scientists – as well as the administrative staff – worked from home where they developed ideas ideas, analyzed data, and wrote proposals and papers. Professor Markus Landthaler coordinates the coronavirus research at the MDC.
In our #QuestionOfTheDay series, he explained the challenges and opportunities related to COVID-19 research:
Dr. Emanuel Wyler is a biochemicist at the MDC Berlin-Mitte (BIMSB) in Landthaler lab. Together with a team of Charité-researcher Professor Christian Drosten and other partners, he investigates the coronavirus.
In our #QuestionOfTheDay series, he answers questions regarding the coronavirus research at the MDC: